HEIDELBERG PHARMA AG O.N. overview

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 06.11.2024 / 10:02 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage...

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024 24.10.2024 / 11:03 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024 Ladenburg, Germany, 24 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug...

EQS-News: Heidelberg Pharma AG / Key word(s): 9 Month figures Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024 10.10.2024 / 07:06 CET/CEST The issuer is solely responsible for the content of this announcement. Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024 HDP-101 clinical trial in Europe and US continues with adjusted protocol and dose optimization on track; sixth patient cohort dosed at 90 µg/kg and patients are still on...

EQS-News: Heidelberg Pharma AG / Key word(s): Study results Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient 01.10.2024 / 17:29 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient Data from the study with the lead ADC candidate,...

EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Forecast Heidelberg Pharma AG Announces Updated Guidance 01-Oct-2024 / 15:27 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma AG Announces Updated...

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024 23.09.2024 / 13:05 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024 Ladenburg, Germany, 23 September 2024...

EQS-News: Heidelberg Pharma AG / Key word(s): Half Year Report Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business 11.07.2024 / 07:05 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published Presentation of preclinical and clinical data of the proprietary ADC...

EQS-News: Heidelberg Pharma AG / Key word(s): AGM/EGM Heidelberg Pharma reports on the results of the Annual General Meeting 2024 21.06.2024 / 11:16 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma reports on the results of the Annual General Meeting 2024 Ladenburg, Germany, 21 June 2024 – Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a...